SGMT - Total Utang marang Modal Sagimet Biosciences Inc

Logo perusahaan publik Sagimet Biosciences (SGMT)

Sagimet Biosciences (SGMT) faces severe pressure from industry leaders and uncertainty regarding trial outcomes. This chart of share prices on GURU.Markets shows a debt-to-equity ratio of 0.01. Sagimet Biosciences (SGMT) is minimizing losses by developing treatments for cancer and metabolic disorders. Furthermore, the business relies on specialized temperature-controlled transport to preserve the properties of its innovative drugs.

SGMT: Total Utang marang Modal Sagimet Biosciences Inc. 21.02.2024 - 01.11.2026

Rincian analitis perusahaan Sagimet Biosciences

- rega lan prakiraan konsensus rega:
Bagan rega Sagimet Biosciences Inc.|SGMT - Bagan tingkat prakiraan
- statistik kapitalisasi pasar:
Kapitalisasi pasar Sagimet Biosciences|SGMT - Nilai Dipunlarasaken Utang lan Kas
- indikator kapitalisasi buku:
Nilai Buku saben Saham Sagimet Biosciences|SGMT - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku sagimet.com|SGMT - Nilai Agregat Aset
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas Sagimet Biosciences|SGMT - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Sagimet Biosciences|SGMT - Gunggung utang perusahaan|Utang marang nilai buku Sagimet Biosciences|SGMT - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Sagimet Biosciences|Rasio cepet sagimet.com
- informasi bathi lan kelipatan valuasi:
SGMT - Penghasilan resik perusahaan
Analisis dhasar perusahaan:Sagimet Biosciences Inc.
Barang utama Sagimet Biosciences Inc

The analyst evaluates the credit quality of Sagimet Biosciences (SGMT) to determine the level of financial risk. The unique development of FASN inhibitors creates high intrinsic business value, reducing reliance on external loans. This debt-to-equity ratio measures the proportion of borrowed funds within the asset financing structure. A decrease in leverage on this chart may indicate either a balance sheet recovery or an underutilization of financial leverage. It is critical for the investor to correlate this trend with liquidity for an objective assessment of stability.

Analisis pesaing Sagimet Biosciences

Utang marang Ekuitas Ascendis Pharma|Madrigal Pharmaceuticals Inc - Utang Agregat marang Ekuitas|Total Utang marang Modal CORT|RYTM (Rhythm Corp) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal AKRO (Akero Therapeutics)|Total Utang marang Modal metsera.com MTSR|MLTX - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi CRNX (Crinetics Pharmaceuticals, Inc.)|NewAmsterdam Pharma N.V. (NAMS) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Soleno Therapeutics Corp|FOLD (Amicus Therapeutics) - Total Utang marang Modal|Total Utang marang Modal 89bio.com|Rasio Total Utang marang Ekuitas AGIO (Agios Pharmaceuticals, Inc.)|GPCR (Structure Therapeutics Inc) - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas MiMedx Group MDXG|RZLT - Rasio Total Utang marang Ekuitas|Lexicon Pharmaceuticals - Total Utang marang Modal|Utang marang Modal mbxbio.com|ALT (Altimmune) - Rasio Total Utang marang Ekuitas|AARD: Utang Agregat marang Modal|BIOA (BioAge Labs Inc.) - Total Utang marang Modal|Total Utang marang Modal Biomea Fusion Corp|Total Utang marang Modal QNCX|Utang marang Ekuitas GUTS (fractyl.com)|Utang marang Ekuitas vTv Therapeutics VTVT|Agape ATP Corp (ATPC) - Utang marang Modal|PLUR - Utang marang Ekuitas|SYBX: Utang marang Ekuitas|LPCN: Total Utang marang Modal|MTNB - Koefisien Total Utang marang Modal|Utang marang Ekuitas Spruce Biosciences, Inc.|Galecto Inc (GLTO) - Koefisien Total Utang marang Modal|Utang marang Ekuitas Carmell Corp (CTCX)|Rasio Total Utang marang Ekuitas Lumos Therapeutics LUMO|Utang marang Ekuitas Organovo Holdings, Inc. ONVO|Koefisien Total Utang marang Modal radiuspharm.com (RDUS)